• Welcome to Phoenix Rising!

    Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of, and finding treatments for, complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia, long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.

    To become a member, simply click the Register button at the top right.

Severe Restriction of Xenotropic Murine Leukemia Virus-Related Virus Replication

urbantravels

disjecta membra
Messages
1,333
Location
Los Angeles, CA
Severe Restriction of Xenotropic Murine Leukemia Virus-Related Virus Replication and Spread in Cultured Human Peripheral Blood Mononuclear Cells

http://jvi.asm.org/cgi/content/abstract/JVI.00046-11v1

J. Virol. doi:10.1128/JVI.00046-11
Copyright (c) 2011, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

Chawaree Chaipan, Kari A. Dilley, Tobias Paprotka, Krista A. Delviks-Frankenberry, Narasimhan J. Venkatachari, Wei-Shau Hu, and Vinay K. Pathak*

HIV Drug Resistance Program, National Cancer Institute at Frederick, Viral Mutation Section and Viral Recombination Section, Frederick, MD 21702, USA

Abstract

Xenotropic murine leukemia virus-related virus (XMRV) is a gammaretrovirus recently isolated from human prostate cancer and peripheral blood mononuclear cells (PBMCs) of patients with chronic fatigue syndrome (CFS). We and others have shown that host restriction factors APOBEC3G (A3G) and APOBEC3F (A3F), which are expressed in human PBMCs, inhibit XMRV in transient transfection assays involving a single cycle of viral replication. However, the recovery of infectious XMRV from human PBMCs suggested that XMRV can replicate in these cells despite the expression of APOBEC3 proteins. To determine whether XMRV can replicate and spread in cultured PBMCs even though it can be inhibited by A3G/A3F, we infected phytohemagglutinin-activated human PBMCs and A3G/A3F-positive and -negative cell lines (CEM and CEM-SS, respectively) with different amounts of XMRV and monitored virus production using quantitative real-time PCR. We found that XMRV efficiently replicated in CEM-SS cells and viral production increased by >4000-fold, but there was only a modest increase in viral production from CEM cells (<14-fold) and a decrease in activated PBMCs, indicating little or no replication and spread of XMRV. However, infectious XMRV could be recovered from the infected PBMCs by cocultivation with a canine indicator cell line, and we observed hypermutation of XMRV genomes in PBMCs. Thus, PBMCs can potentially act as a source of infectious XMRV for spread to cells that express low levels of host restriction factors. Overall, these results suggest that hypermutation of XMRV in human PBMCs constitutes one of the blocks to replication and spread of XMRV. Furthermore, hypermutation of XMRV proviruses at GG dinucleotides may be a useful and reliable indicator of human PBMC infection.